Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Kite Pharma
Pharma
FDA removes barrier to CAR-Ts; move likely to boost uptake
The FDA removed the REMS requirements for currently approved BCMA- and CD19-directed CAR-T therapies and reduced certain post-infusion restrictions.
Angus Liu
Jun 27, 2025 11:14am
BioNTech to wind down cell therapy manufacturing in Maryland
Jun 18, 2025 10:23am
Gilead's Kite taps Amgen alum as new global commercial head
Jan 16, 2025 10:14am
Daiichi, Fosun, Yuhan and more—Fierce Pharma Asia
Sep 27, 2024 10:15am
Gilead's Kite exits China cell therapy JV with Fosun Pharma
Sep 19, 2024 4:23pm
Kite will evaluate Cellares' cell therapy manufacturing platform
Jun 27, 2024 8:00am
